Introduction
Alterations in two tyrosine kinase genes, ABL1 and JAK2, account for the majority of myeloproliferative neoplasms. The BCR-ABL1 fusion is the hallmark of chronic myeloid leukemia while JAK2 point mutations are found in most cases of polycythemia vera and in about 50% of patients with essential thrombocythemia or primary myelofibrosis. [1] [2] [3] Essential thrombocythemia and primary myelofibrosis can also be caused by mutations in the thrombopoietin receptor, which activates JAK2. 4 In rare cases of myeloproliferative neoplasms, mutations are found in other tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR) α or b.
5 Chromosomal rearrangements of the PDGFR genes produce constitutively activated fusion receptors that are responsible for myeloid neoplasms associated with eosinophilia. 5 Like chronic myeloid leukemia, these diseases are efficiently treated with tyrosine kinase inhibitors such as imatinib. 6 Whether myeloproliferative neoplasms associated with JAK2 mutations can also benefit from a treatment based on specific tyrosine kinase inhibitors is currently under investigation. 7 The best characterized PDGFR fusion product arises from the translocation between the genes TEL (also known as ETV6) and PDGFRB, which encodes PDGFRb. The fusion protein retains the N-terminal pointed (PNT) domain of TEL and the PDGFRb tyrosine kinase domain. The PNT domain promotes the oligomerization of the hybrid protein, mimicking ligand-induced dimerization and thereby activating the PDGFRb kinase domain by trans-phosphorylation. 5 In addition, we showed that this fusion protein escapes ubiquitination and degradation, which PDGF receptors normally undergo upon activation. 8 TEL-PDGFRb and most other PDGFRb hybrid proteins retain the PDGFRb transmembrane domain, which does not affect the cytosolic localization of these oncoproteins but contributes to their acquiring the optimal active conformation. 9 TEL-PDGFRb was shown to activate various signal transduction mediators, among which the transcription factor STAT5 plays a prominent role. 10 Whether the same mechanisms apply to other PDGFRB translocation products is not clear, as none of the alternative fusion partners includes a PNT domain. Various types of dimerization domains, such as coiled coils, were suggested to substitute for the PNT in these proteins, but this has not been established experimentally. 5 In HIP1-PDGFRb, the coiledcoil/leucine zipper domain is dispensable for oligomerization and cell transformation. 11 In another hybrid, H4-PDGFRb, a similar domain was shown to be required to sustain Ba/F3 cell proliferation but its function was not further studied. 12 In BCR-ABL1, the coiled-coil domain of BCR promotes multimerization and activation of the tyrosine kinase required for the BCR-ABL-induced cell transformation. A mutant lacking this domain fails to induce myeloproliferative neoplasms in mice. 13 Smith et al. showed that the sole function of the BCR-ABL coiled-coil domain is to disrupt the autoinhibited conformation through oligomerization and intermolecular autophosphorylation. 14 We recently identified a new chromosomal translocation between the potential tumor suppressor gene KANK1 and PDGFRB in a case of thrombocythemia.
15 KANK1 (also known as KANK or ANKRD15) is part of a family of proteins that regulates actin polymerization and cell motility. 16 These proteins feature multiple N-terminal coiledcoil domains and C-terminal ankyrin domains. Loss of KANK1 expression has been associated with renal cell carcinoma and cerebral palsy. 17, 18 We have shown that the KANK1-PDGFRb fusion protein (KPb) stimulates Ba/F3 cell growth and the activation of the STAT5 transcription factor. 15 In the present study, we further analyzed the mechanisms of hematopoietic cell transformation by KPb. Since JAK2 is a key mediator of essential thrombocythemia and was shown to be activated by wild-type PDGF receptors in different cell types, [19] [20] [21] we first tested whether JAK2 activates STAT downstream of KPb. Next, we identified the domains responsible for signaling and activation of KPb in hematopoietic cells.
Design and Methods

Antibodies, inhibitors and constructs
Anti-PDGFRb (958), anti-phosphotyrosine (PY99) and anti-STAT5 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho STAT5 (tyr694), anti-phospho JAK2 (tyr1007-1008), anti-phospho PLCγ1 (tyr783) and antiphospho ERK1/2 (thr202 and tyr204) antibodies were purchased from Cell Signaling. Mouse monoclonal antibodies against FLAG (M5) and b-actin (clone AC-15) were purchased from Sigma and the anti-JAK2 antibody from Millipore (#06-1310). The anti-PDGFR (CED), anti-PLCγ1 and anti-ERK1 (EET) rabbit polyclonal antisera have been described elsewhere. 22 JAK inhibitor I, UO126, PD98059, and SU6656 were obtained from Calbiochem and imatinib from Novartis. All cytokines were purchased from Peprotech.
The KPb sequence was cloned in the lentiviral vector pTM898-neo as described elsewhere. 15 All KANK1 constructs correspond to KANK1-S, which is the predominant isoform in hematopoietic cells. 23 (Medves et al., unpublished data) The following mutants carrying deletions of the KANK1 part of KPb were generated: m1, residues 159 to 739; m2, residues 238 to 739; m3, residues 343 to 739; m4, residues 002 to 287; m5, residues 2 to 202 and m6, residues 159 to 287; m8, residues 100 to 739; m11, residues 343 to 641; m12, residues 642 to 739; m14, residues 002 to 451 (residue numbering according to SWISS-PROT accession number #Q6PIB3). KANK1 fragments were generated by PCR amplification and introduced by restriction (AgeI, NheI) into the pTM898-neo-KPb vector. The KANK1 residues present in KPb (residues 1 to 739, named K1-739) were also cloned separately in pTM898-neo. All constructs were FLAG-tagged in the N-terminus region and checked by sequencing. TEL-PDGFRβ and JAK2-V617F constructs were described previously. 8, 24 Transfection, infection, luciferase and thymidine incorporation assay Lentiviral particles were produced by HEK-293T cells, which were transfected by the calcium phosphate method, as described previously. 8, 15 The interleukin (IL)3-dependent Ba/F3 cells were infected twice 15 and selected in the presence of G418. Transduced cells were cultured in the presence of fetal calf serum and IL3, except for the experiments whose results are presented in Figures  1 and 2 , in which cells growing autonomously without IL3 were used.
γ-2A JAK2-deficient human fibrosarcoma cells were transfected using lipofectamine with pGRR5-luc or pLHRE-luc reporters and the pEF-b-galactosidase vector as an internal control, as described previously.
25 pGRR5-luc contains five copies of the STAT-binding site of the FcγRI gene inserted upstream of the minimal TK promoter and a luciferase gene. 26, 27 pLHRE-luc harbors tandem copies of the STAT5-inducible lactogenic hormone response element (LHRE) of the rat b-casein gene promoter. 25 Twenty-four hours after transfection, cells were lysed and luciferase and b-galactosidase activities were recorded as described elsewhere. [28] [29] [30] 
Flow cytometry
Intracellular staining was performed as described previously and analyzed by flow cytometry. 9 Briefly, about 10 6 cells were washed to remove IL3 and starved for 4 h in the presence of imatinib or JAK inhibitor I. As a positive control, some cells were restimulated with IL3 after starvation (data not shown). Cells were fixed with 2% formaldehyde in phosphate-buffered saline for 10 min at 37°C and then permeabilized with methanol on ice for 30 min. After having been washed twice with HAFA buffer (Hanks' buffer complemented with 3% fetal bovine serum and 1% NaN3), the cells were incubated with Alexa-Fluor 647-conjugated antibodies specific for phospho-STAT5 (tyrosine 694) or phospho-ERK1/2 (threonine 202 and tyrosine 204) (BD Transduction Laboratories) or phycoerythrin-conjugated anti-PDGFRb (#958, Santa Cruz Biotechnology) for 1 h at room temperature. Cells were washed and analyzed by flow cytometry. Results are expressed as a percentage of positive cells and normalized using KPb as a reference.
Immunoprecipitation and western blot
HEK 293T cells were transiently transfected with KPb or mutants and/or with K1-739 and lysed 24 h after transfection.
Cell lysates were immunoprecipitated for 4 h with 1 mg of antiPDGFRb antibody at 4°C to capture KPb or mutants proteins. Antibody complexes were collected by adding protein-A/G Ultralink (Pierce) for 2 h at 4°C or protein-A/G magnetic beads (New England Biolabs) for 1 h at 4°C, washed extensively and analyzed by western blot with the anti-FLAG or the anti-PDGFR antibody as described. 9, 22 To assess KPb phosphorylation, Ba/F3 cells stably expressing the constructs were lyzed and KPb was immunoprecipitated overnight and analyzed by immunoblotting using anti-phosphotyrosine antibodies as described elsewhere.
9,22
CD34
+ cell isolation, infection and culture
Cord blood units unsuitable for preservation were used following a procedure approved by the ethics committee of the medical faculty (reference B40320108411) within 24 h of collection. Leukocytes were isolated from fresh cord blood by centrifugation over a Ficoll-Paque density-gradient (GE Healthcare) and CD34 + cells were purified using the EasySep kit (StemCell Technologies, Vancouver, Canada). Cell purity was routinely checked by flow cytometry with an anti-CD34 antibody (Becton Dickinson) and was above 80%. Cells were cultured in Iscove's modified Dulbecco's medium (IMDM), supplemented with 20% fetal bovine serum, 10 U/mL penicillin, 1.0 µg/mL streptomycin, and 0.24 mM L-asparagine, 0.55 mM L-arginine, 1.5 mM L-glutamine in the presence of recombinant human stem cell factor and FLT3 ligand (SCF and FLT3L, respectively, both at 25 ng/mL). Lentiviral particles were produced with the VSV-G envelope protein and concentrated using Centricon Plus-70 (Millipore). 15 One day after haematologica | 2011; 96(10) 5 CD34 + cells were re-suspended in 0.5 mL of growth medium and incubated for 24 h with lentiviral particles (0.3 mL) and polybrene (8 mg/mL). The cells were then washed and re-suspended in fresh growth medium (0.5 mL) with new viral supernatant (0.3 mL) and polybrene. Cells were centrifuged at 400 x g for 2 h, washed and cultured as described above. After 24 h, transduced cells were seeded at 30000 cells/mL in two different conditions: in the absence of cytokines or in the presence of SCF (20 ng/mL) and FLT3L (20 ng/mL), thrombopoietin (20 ng/mL) and IL6 (1 ng/mL).
Statistics
Experiments were repeated at least three times with identical results. In most figures, the average of multiple replicate experiments is shown with the standard error of the mean (SEM), unless otherwise stated. Statistical analysis was performed using the Student's t-test (*P<0.05; **P<0.01; ***P<0.001).
Results
Role of JAK2 in KANK1-PDGFRb-induced STAT5 activation and cell proliferation
Wild-type PDGF receptors are capable of activating JAK2 in several cell types, [19] [20] [21] raising the possibility that JAK2 plays a role in hematopoietic cell transformation by KPb. We first analyzed the phosphorylation of JAK2 by western blot in Ba/F3 cells expressing KPb, which proliferate in the absence of IL3. 15 As a positive control, we used cells treated with IL3 or expressing JAK2-V617F. Figure 1A clearly shows that JAK2 phosphorylation was not detectable in cells expressing KPb. We next measured the proliferation rate of these cells in the presence of imatinib or JAK inhibitor I, which selectively blocks JAK kinases ( Figure 1B ). Ba/F3-KPb proliferation was blunted by imatinib, as previously shown, 15 but was not affected by JAK inhibitor I. By contrast, this inhibitor blocked proliferation driven by JAK2-V617F or IL3, which was not affected by imatinib.
We have shown that KPb induces the activation of STAT5, which plays an important role in Ba/F3 proliferation. 15, 27 KPb-induced STAT5 phosphorylation was measured by flow cytometry and was not affected by JAK inhibitor I, in line with the cell proliferation results ( Figure  1C ). To confirm these observations, we analyzed the activation of STAT by KPb using luciferase reporter constructs in γ2A cells, which do not express JAK2. 25 KPb was capable of stimulating the activity of two promoters containing STAT responsive elements, namely GRR5 and LHRE ( Figure 1D and 1E, respectively). The GRR5 promoter can bind multiple STAT while LHRE is more specific for STAT5. 25, 27 Wild-type JAK2 transfection did not modify the response to KPb. By contrast, erythropoietin stimulated STAT activity only if JAK2 was reintroduced by co-transfection, in agreement with previously published results. 25 Altogether these observations show that JAK2 is not involved in STAT activation and cell transformation by KPb. Since JAK inhibitor I also targets other JAK kinases, these are unlikely to play a role in the autonomous signaling by KPb in Ba/F3-KPb. SRC is another tyrosine kinase that is activated by PDGF receptors and is capable of activating STAT proteins. However, a specific inhibitor of SRC family kinases had no impact on STAT5 phosphorylation (Online Supplementary Figure S1 ). The PDGFR kinase domain of KPb may directly phosphorylate STAT5, as described for the wild-type receptor in other cell types.
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Signaling pathways activated by KPb
We next compared the signaling pathways activated by KPb, TEL-PDGFRb and JAK2-V617F by western blot in Ba/F3 cells stably expressing these oncogenes. As expected, the three oncogenes induced the phosphorylation of STAT5 and ERK1/2 (Figure 2A ). KPb and TEL-PDGFRb, unlike JAK2-V617F, also induced strong phosphorylation of phospholipase Cγ (Figure 2A ). Specific kinase inhibitors were used to demonstrate the specificity of the signal. In conclusion, KPb was more comparable to TEL-PDGFRb than to JAK2-V617F in terms of signaling. Activation of ERK1/2 and phospholipase Cγ by KPb was consistent with signal transduction by wild-type PDGF receptors. 33 To test the importance of ERK signaling in cell proliferation, we used two different MEK inhibitors, namely U0126 and PD98059, which block ERK1 and ERK2 activation. 28, 34 Both inhibitors abolished proliferation of the Ba/F3 cell lines ( Figure 2B ). Using a similar approach, we did not find any convincing evidence for a role of the phospholipase C pathway in Ba/F3-KPb cell proliferation (data not shown). Further studies are needed to determine whether PLCγ contributes to KPb-induced signaling.
Identification of KANK1 domains required for Ba/F3-KPb cell proliferation
To further characterize the mechanism of activation of KPb, we constructed mutants with progressive deletions of the N-terminal KANK1 part, which includes multiple coiled-coil (CC) domains ( Figure 3A ). Mutants were introduced in Ba/F3 cells using lentiviral particles and their expression was tested by western blot ( Figure 3C) . Deletion of the first CC domain (m1 mutant) increased the protein expression significantly. However, at the mRNA level measured by quantitative PCR, m1 expression was not increased compared to KPb (data not shown). The difference in protein expression between KPb and m1 was partially compensated for by treating KPb cells with the proteasome inhibitor MG132, pointing to an increased protein stability of the mutants compared to KPb (data not shown).
When long-term proliferation in the absence of IL3 was assessed, only m1 and, to a lesser extent, m2, but not m3 or m12, were able to sustain Ba/F3 cell growth and produce an autonomous cell line in a reproducible manner, indicating that the presence of CC is mandatory for cell transformation. To further compare the activity of all the mutants, we measured thymidine incorporation a few hours after removing IL3. Deletion of one, two or three CC domains progressively decreased Ba/F3 proliferation in the absence of IL3, even though these mutants were expressed at a higher level. A weak but significant proliferation was still detectable with cells expressing the m3 mutant, which lacks the 342 amino acids encoding the CC domains. Deletion of 641 amino acids (m12 mutant) abolished Ba/F3 cell growth ( Figure 3B ). This inactive mutant retained the fourth CC domain, which is thus unable to activate KPb. Finally, deletion of the first 99 amino acids located before the CC (m8 mutant) or PDGFRb Ig5 domain (m13 mutant) did not affect the growth of Ba/F3-KPb (Online Supplementary Figure S2 and   15 ). Altogether these results pointed to two important KANK1 regions in KPb: the three first CC and the domain located after (amino acids 343-641). We constructed two additional mutants, m11 and m14, in which only one of these two regions of KANK1 was present. Both mutations decreased proliferation significantly ( Figure 3B ).
The phosphorylation of STAT5 and ERK1/2, measured by flow cytometry, was significantly decreased when CC were progressively deleted (m2 and m3 mutants), and reached the background level in cells expressing the m12 mutant ( Figure 3B ). ERK phosphorylation was more affected than STAT5 phosphorylation. Collectively these results show that multiple domains are required for cell transformation and signaling induced by KPb.
Coiled coils are not essential for KPb oligomerization and autophosphorylation
Based on the study of TEL-PDGFRb, it is usually
S. Medves et al.
1410
haematologica | 2011; 96(10) assumed that oligomerization domains, such as CC, found in the partner fused to PDGFR are implicated in the selfassembly of hybrid molecules. In addition, the CC domains of wild-type KANK1 were suggested to promote KANK1 dimerization (unpublished data from the study by Kakinuma et al. 16 ). This prompted us to investigate whether KPb forms oligomers though its CC domains. We tested the ability of KPb and mutants to bind the first 739 residues of KANK1 (K1-739) by co-immunoprecipitation after transfection in 293T cells (Figure 4) . As expected if the KANK1 part of the hybrid mediates oligomerization, KPb was able to bind to K1-739. Surprisingly, the deletion of the three N-terminal CC domains of KPb did not impair the association with K1-739. Thus the decreased transformation activity of the mutants lacking these CC domains cannot be explained by a defect in oligomerization. Further deletion (m12 mutant) abolished the interaction of mutant KPb with the K1-739 fragment. Analysis of additional mutants suggested that the first CC alone (m5), but not the second one (m6), was able to induce KPb oligomerization ( Figure 4 ). These two mutants did not support IL3-independent Ba/F3 proliferation (Online Supplementary Figure S2 ) or STAT5 phosphorylation (data not shown). Collectively these observations suggested that several domains promote the oligomerization of KPb, including the first CC domain and another sequence located between residues 343 to 641 of KANK1. This sequence is partially conserved in Danio rerio KANK1, but does not share homology with any other protein or with the other ankyrin repeat family members KANK2, KANK3 or KANK4. We will refer to this conserved region as KANK1 oligomerization domain (KOD, see hatched regions in Figures 3 and 4) . By contrast to CC, most of the KOD sequence is predicted to adopt a b-sheet structure.
To confirm these results, we performed protein crosslinking experiments with lysates of Ba/F3 cells expressing KPb. 9 Addition of the BS3 cross-linker induced high molecular weight oligomeric KPb complexes, while the monomeric form of KPb disappeared (Online Supplementary Figure S3B) . The size of the bands compared to standards was consistent with homotrimeric KPb complexes and heavier polymers, but no dimer. The K1-739 KANK1 fragment alone also formed trimers and oligomers after cross-linking, confirming that oligomerization is driven by the KANK1 part of the fusion. Similar results were obtained with mutants lacking N-terminal CC domains. Mutant m11, which lacks all four CC domains and retains only the KOD domain fused to PDGFRb was still efficiently cross-linked. By contrast, the combined deletions of the first CC domain and the KOD domain (m12) prevented efficient cross-linking of monomers, the amount of which was unchanged even at high BS3 concentrations (Online Supplementary Figure S3C) . Nevertheless, a small proportion of KPb m12 was still in the form of high molecular weight complexes. This may represent residual oligomerization, background protein cross-linking and/or interaction with other proteins.
Ligand-induced dimerization of wild-type PDGF receptors activates the kinase domain and induces the receptor autophosphorylation on tyrosines. We have shown that KPb is constitutively phosphorylated on tyrosines in a process that is highly sensitive to imatinib. 15 To determine which KANK1 sequences are required for autophosphorylation, we performed immunoprecipitation followed by immunoblotting with anti-phosphotyrosine antibodies. Figure 5A shows that KPb and mutants m1, m2 and m3 were strongly phosphorylated, in contrast to mutant m12, in agreement with the oligomerization data. However, when the total amount of each mutant KPb protein was taken into account, the normalized tyrosine phosphorylation was decreased by about 60% in m1, m2 and m3 (see figure legend for details), suggesting that the kinase activity of these mutants was lowered, which was compensated by their higher expression level compared to KPb. Interestingly, when KPb was co-expressed with KANK1 wild-type or the K1-739 fragment, both proteins were also found phosphorylated on tyrosine residues ( Figure 5B ). This indicates that the PDGFR kinase domain is able to phosphorylate sites in the KANK1 part of KPb, creating new docking sites for signaling proteins, in addition to the 11 characterized phosphorylated sites of PDGFRb.
KPb induces the proliferation of human hematopoietic progenitor cells
To confirm our results in a more physiological model, we introduced KPb into human CD34 + cells isolated from cord blood. This population of cells is highly enriched in hematopoietic progenitors and stem cells, which are the origin of myeloproliferative disorders. We observed that cells transduced with KPb proliferated in the absence of cytokines, while cells infected with control lentivirus did not ( Figure 6A ). Cell proliferation reached a plateau and stopped after about 2 weeks, indicating that cells were not immortalized. In the presence of an optimal growth factor cocktail (i.e. thrombopoietin, SCF, FLT3L and IL6), KPb expression further enhanced cell growth ( Figure 6B ). We introduced the KPb mutants into CD34 + cells and controlled their expression by flow cytometry on permeabilized cells with an anti-PDGFRb antibody ( Figure 6C ). In line with the results obtained in Ba/F3 cells, the deletion of CC domains decreased cell proliferation significantly. KPb also activated STAT5 in these cells ( Figure 6D ), which was much reduced by deletion of the CC domains. These results confirmed the importance of the CC domains for KPb activity in hematopoietic cells. A summary of our results is presented in Online Supplementary Figure S4 .
Discussion
The unique association of KANK1-PDGFRb with thrombocythemia prompted us to test whether this hybrid oncoprotein could share signal transduction pathways with JAK2-V617F. We showed that KPb does not signal via JAK2, unlike wild-type PDGFR, which can activate JAK2 in various types of cells. [19] [20] [21] Similar results were published regarding cells expressing TEL-PDGFRb. 35 Like JAK2-V617F and TEL-PDGFRb, KPb activated ERK1/2 and STAT5. The role of STAT5 in myeloproliferative neoplasms is well established. This factor is activated downstream of all mutated kinases found in myeloproliferative neoplasms so far. The ERK pathway is an important mediator of cell transformation by BCR-ABL and was recently suggested to play a role in myeloproliferative neoplasm downstream mutant thrombopoietin receptors. 36 Even though TEL-PDGFRb and KPb have been associated with different myeloproliferative neoplasms, we did not identify any difference in signaling by these two oncogenes.
Our data demonstrate that KPb forms oligomers through interactions between various domains of the KANK1 part of the fusion protein, like most oncogenic fusion kinases. The cross-linking analysis suggested the existence of KPb homotrimers and polymers ( Figure 5C ). This is also supported by the observation that, although K1-739 binds to KPb, its over-expression did not reduce KPb phosphorylation on tyrosines, as would be expected if KPb were a dimer (data not shown CC domains are present in most hybrid PDGFR and are generally thought to induce oligomerization. Although the first CC domain could mediate KPb oligomerization, these domains were not absolutely essential because the KOD domain, located after the CC domains, could also do it. Thus the coiled coils and the KOD appeared to be redundant for oligomerization. All mutants that were able to form oligomers were phosphorylated on tyrosines. However, the normalized tyrosine phosphorylation indicated that the mutant polypeptides were less phosphorylated. Although this is likely to reflect decreased kinase activity of the mutants, it is also possible that the phosphorylation of specific PDGFRb sites is affected by the mutations. Based on this potentially reduced kinase activity and on the reduced signaling efficiency of the mutants, we hypothesize that multiple oligomerization domains (CC and KOD) are required to generate the optimal active conformation of KPb. This is reminiscent of the role of the transmembrane domain of TEL-PDGFRb, which is required for signaling and cell transformation but not for oligomerization and autophosphorylation. 9 In that case, we suggest that the transmembrane domain is required to adopt a conformation that is competent for signaling. In line with this hypothesis, wild-type PDGF receptor dimerization is not sufficient to switch on the kinase domains, which must be properly oriented to activate each other. 37 In addition, it is also possible that the KANK1 part of KPb plays a direct role in signaling. KANK1 CC domains were shown to bind to IRSp53, 38 and could recruit other signaling proteins that help STAT5 or ERK activation. Phosphorylated tyrosine residues of the KANK1 part of KPb may also act as docking sites for signaling mediators containing SH2 domains, since we showed that the PDGFR kinase domain can phosphorylate wild-type KANK1 and the K1-739 fragment on tyrosine residues. Analysis of the KANK1 sequence revealed one potential binding site for STAT5 (DNY612LV), compared to other known STAT5 recruitment sites. 26, 39 However, the KPb-Y612A mutation did not affect STAT5 phosphorylation or growth stimulation (Online Supplementary Data, unpublished data). Ten other tyrosines are located in the KANK1 part of KPb.
The subcellular localization of mutated tyrosine kinases is an important determinant of their oncogenicity. 5 We confirmed that KPb is located in the cytosol of transfected cells (data not shown), like wild-type KANK1 and TELPDGFRb.
9,16 However, we did not rule out the possibility that KPb associates with a particular cytosolic structure, which could regulate signaling.
In conclusion, our results show that multiple oligomerization domains of KPb are required for signaling and hematopoietic cell proliferation. Deciphering how these domains are organized in KPb will require further structural studies. These data also imply that complex structural constraints dictate whether a given chromosomal breakpoint will produce an active hybrid kinase. 
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